相关实验视频
Updated: May 24, 2025

08:36
In Vitro Assay to Study Tumor-macrophage Interaction
Published on: August 1, 2019
7.5K
与癌症相关的巨类细胞作为固体瘤的预后生物标志物
Anthony Pirrello1,2, Murray Killingsworth3, Kevin Spring4
1Li Ka Shing Cell and Gene Therapy Program, The University of Sydney, Camperdown, 2050, NSW, Australia.
The journal of liquid biopsy
|March 3, 2025
概括
与癌症相关的巨细胞 (CAMLs) 是固体瘤的新型血液生物标志物. 本综述探讨了它们在癌症预后和治疗监测方面的潜力.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 与癌症相关的巨细胞 (CAMLs) 是血液中发现的髓状细胞,与癌症有关.
- CAML正在成为固体瘤的潜在液体活检生物标志物.
- 这些细胞在各种癌症中被检测到,但在健康人群中没有.
研究的目的:
- 审查CAMLs的当前研究.
- 探索CAMLs在癌症管理中的未来临床实用性.
- 为了解决有关CAML检测,起源和功能的知识差距.
主要方法:
- 对现有的CAML研究进行文献综述.
- 对报告癌症患者中CAML检测的研究分析.
- 讨论对临床决策的影响.
主要成果:
- 在患有肺癌,胰腺癌,乳腺癌,食道癌和结直肠癌的患者的血液样本中可以检测到CAML.
- 在健康个体中尚未确定CAMLs.
- 最佳的检测方法,起源和功能需要进一步调查.
结论:
- 作为癌症预后和监测治疗反应的液体活检生物标志物,CAMLs显示出前景.
- 需要进一步的研究,以充分阐明它们的作用,并优化临床应用的检测.
- 在固体瘤管理中,CAMLs可以指导临床决策.
相关概念视频
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Cancer Survival Analysis
319
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
319

